Last reviewed · How we verify
GSK3389245A_HD GROUP — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GSK3389245A_HD GROUP (GSK3389245A_HD GROUP) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK3389245A_HD GROUP TARGET | GSK3389245A_HD GROUP | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK3389245A_HD GROUP CI watch — RSS
- GSK3389245A_HD GROUP CI watch — Atom
- GSK3389245A_HD GROUP CI watch — JSON
- GSK3389245A_HD GROUP alone — RSS
Cite this brief
Drug Landscape (2026). GSK3389245A_HD GROUP — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk3389245a-hd-group. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab